From drug discovery to daily supplements and digital systems, health is becoming more programmable.
Lilly doubles down on AI drug discovery
Eli Lilly signed a new deal with Insilico Medicine worth up to $2.75B.
- The deal gives Lilly rights to develop and commercialize medicines discovered through Insilico’s AI platform, expanding a relationship that began in 2023.
- Investing in AI, it also teamed up with Nvidia on a $1B co-innovation lab.
Using GLP-1profits to fund the next era of drug development, Lilly is following the new pharma playbook, prioritizing AI as R&D to discover therapies tied to aging, metabolic health, and long-term resilience.
Social media design faces scrutiny
A California jury found Meta and Google liable for harms tied to compulsive youth social media use, awarding $6M in damages in a case centered on product design.
- Features like infinite scroll, autoplay, notifications, and beauty filters were found to make platforms like Instagram and YouTube effectively addictive for kids.
- For the first time, the court ruling found social media companies liable for engineering products that harm developing brains.
The verdict gives momentum to cases related to digital health harms, arguing that companies are accountable on the basis of product safety issues.
Create scales creatine supps
Create Wellness raised a $20M Series B to establish creatine as a daily habit.
- The company has sold more than 100M gummies to date and grew 4x last year.
- It also expanded retail distribution through Target, The Vitamin Shoppe, and Sprouts.
- Most recently, it launched a new powder combining creatine and electrolytes.
As female adoption rises and more brands enter the category, winning brands are focused on format, habit formation, and making creatine feel as essential as daily vitamins.
